Notably, favorable results have been obtained from clinical trials using pegylated arginine deiminase (ADI-PEG20; Feun and Savaraj, 2006) to treat ASS1-deficient cancers including hepatocellular carcinoma and advanced melanoma (Kuo et al., 2010). Here, ASS1 is linked to hepatocellular carcinoma.